Pierluigi Masciopinto
Overview
Explore the profile of Pierluigi Masciopinto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
22
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tamma R, Ingravallo G, Gaudio F, dAmati A, Masciopinto P, Bellitti E, et al.
Cancers (Basel)
. 2023 Jun;
15(10).
PMID: 37345141
Although classical Hodgkin lymphoma (CHL) is typically curable, 15-25% of individuals eventually experience a relapse and pass away from their disease. In CHL, the cellular microenvironment is constituted by few...
2.
Gaudio F, Dicataldo M, Di Giovanni F, Cazzato G, dAmati A, Perrone T, et al.
Clin Lymphoma Myeloma Leuk
. 2023 May;
23(8):599-605.
PMID: 37147150
Introduction: Mantle cell lymphoma (MCL) is a rare type of lymphoma, which despite improvements in therapies in recent decades, remains an incurable disease. There is currently no reliable marker of...
3.
Gaudio F, Loseto G, Bozzoli V, Scalzulli P, Mazzone A, Tonialini L, et al.
Ann Hematol
. 2023 Jan;
102(2):385-392.
PMID: 36645458
Checkpoint inhibitors have significantly changed the prognosis of patients with relapsing refractory classical Hodgkin's lymphoma (cHL), demonstrating excellent results in heavily pretreated patients. However, there is still limited data on...
4.
Molecular Features and Diagnostic Challenges in Alpha/Beta T-Cell Large Granular Lymphocyte Leukemia
Gaudio F, Masciopinto P, Bellitti E, Musto P, Arcuti E, Battisti O, et al.
Int J Mol Sci
. 2022 Nov;
23(21).
PMID: 36362180
Large granular lymphocyte leukemia is a rare chronic lymphoproliferative disease of cytotoxic lymphocytes. The diagnosis, according to the WHO, is based on a persistent (>6 months) increase in the number...
5.
Bellitti E, Masciopinto P, Musto P, Arcuti E, Mastracci L, Opinto G, et al.
Curr Oncol
. 2022 Sep;
29(9):6115-6124.
PMID: 36135049
Aims: To investigate a possible relationship between DLBCL and cHL, in this retrospective study of 269 patients with newly diagnosed cHL treated at Bari University Hospital (Italy) between 2007 and...
6.
Masciopinto P, Bellitti E, Arcuti E, Battisti O, Cazzato G, Perrone T, et al.
Clin Lymphoma Myeloma Leuk
. 2022 May;
22(8):e745-e750.
PMID: 35501257
Lymphoproliferative diseases arise when the physiological mechanisms that control the proliferation of T and B lymphocytes are disrupted, resulting in an uncontrolled and autonomous increase in immune cells leading to...
7.
Laddaga F, Masciopinto P, Nardelli C, Vacca M, Masciandaro P, Arcuti E, et al.
Br J Haematol
. 2021 Aug;
196(1):110-115.
PMID: 34462914
The outcome of patients with Hodgkin lymphoma (HL) has improved significantly in recent years, and now attention is increasingly being focused on the well-being of these young patients. This study...
8.
Masciopinto P, DellOlio G, De Robertis R, Specchia G, Musto P, Albano F
J Clin Med
. 2020 Oct;
9(11).
PMID: 33114226
The connection between autoimmune disease (AID) and lymphoproliferative disorders is a complex bidirectional relationship that has long been a focus of attention by researchers and physicians. Although advances in pathobiology...